Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy

Abstract

11542 Background: The standard of care when treating patients with metastatic or locally recurrent HER2-positive breast cancer includes using T alone or in combination with chemotherapy. Patients whose disease responds to trastuzumab generally continue therapy until disease progression. Little is known about women with limited disease volume who respond to T and receive definitive local-regional treatment. Can T be stopped in these patients? At a cost upwards of $40,000/year and an FDA recommended weekly dosing interval, any information on this topic would be valuable. Methods: Case series of women seen by a single medical oncologist. Patients had HER2-positive metastatic or locally recurrent breast cancer whose disease was resectable or could be encompassed within a radiation therapy (RT) port. This is not a clinical trial. Patients were treated according to the best medical judgment of the physicians involved. Results: Six patients are described. Two patients had chest wall recurrence (skin) in a previo...